Phenotype–genotype spectrum of AAA syndrome from Western India and systematic review of literature

Hiren Patt¹, Katrin Koehler², Sailesh Lodha³, Swati Jadhav¹, Chaitanya Yerawar¹, Angela Huebner², Kunal Thakkar¹, Sneha Arya¹, Sandhya Nair¹, Manjunath Goroshti¹, Hosahithlu Ganesh⁴, Vijaya Sarathi⁵, Anurag Lila¹, Tushar Bandgar¹ and Nalini Shah¹

¹Department of Endocrinology, Seth G.S. Medical College & KEM Hospital, Mumbai, Maharashtra, India
²Department of Paediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
³Eternal Hospital, Jaipur, Rajasthan, India
⁴Department of Endocrinology, AJ Institute of Medical sciences, Mangalore, India
⁵Department of Endocrinology, Vydehi Institute of Medical Sciences and Research Center, Bengaluru, India

Abstract

Objective: To study genotype–phenotype spectrum of triple A syndrome (TAS).

Methods: Retrospective chart analysis of Indian TAS patients (cohort 1, n=8) and review of genotyped TAS cases reported in world literature (cohort 2, n=133, 68 publications).

Results: Median age at presentation was 4.75 years (range: 4–10) and 5 years (range: 1–42) for cohorts 1 and 2, respectively. Alacrima, adrenal insufficiency (AI), achalasia and neurological dysfunction (ND) were seen in 8/8, 8/8, 7/8 and 4/8 patients in cohort 1, and in 99, 91, 93 and 79% patients in cohort 2, respectively. In both cohorts, alacrima was present since birth while AI and achalasia manifested before ND. Mineralocorticoid deficiency (MC) was uncommon (absent in cohort 1, 12.5% in cohort 2). In cohort 1, splice-site mutation in exon 1 (p.G14Vfs*45) was commonest, followed by a deletion in exon 8 (p.S255Vfs*36). Out of 65 mutations in cohort 2, 14 were recurrent and five exhibited regional clustering. AI was more prevalent, more often a presenting feature, and was diagnosed at younger age in T group (those with truncating mutations) as compared to NT (non-truncating mutations) group. ND was more prevalent, more common a presenting feature, with later age at onset in NT as compared to T group.

Conclusion: Clinical profile of our patients is similar to that of patients worldwide. Alacrima is the earliest and most consistent finding. MC deficiency is uncommon. Some recurrent mutations show regional clustering. p.G14Vfs*45 and p.S255Vfs*36 account for majority of AAAS mutations in our cohort. Phenotype of T group differs from that of NT group and merits future research.

Introduction

Triple A syndrome (TAS, MIM #231550) or Allgrove’s syndrome is an autosomal recessive disorder, characterized by clinical triad of alacrima, adrenal insufficiency (AI) and achalasia cardia. TAS patients may have varied neurological dysfunction (ND) in the form of distal sensory motor polyneuropathy, autonomic dysfunction, dementia, mental retardation, bulbospinal amyotrophy, optic atrophy, parkinsonian features, dysarthria, dystonia and chorea (1). Other features described in TAS include microcephaly, short stature, dysmorphic facies with long
narrow face, long philtrum, down-turned mouth, thin upper lip, lack of eyelashes, poor wound healing, palmar and plantar hyperkeratosis, scoliosis, osteoporosis, long QT syndrome and hypolipoproteinemia type IIIb (2).

Long time after the initial description of TAS, two groups independently described AAAS (achalasia-addisonianism-alacrimia syndrome) gene as the causative gene for this syndrome, in years 2000 and 2001, respectively (3, 4, 5). AAAS gene is located on chromosome 12q13 and encodes for ALADIN (alacrima, achalasia, adrenal insufficiency, neurologic disorder) protein, a member of WD (tryptophan-aspartic acid) repeat containing proteins’ family, which localizes to nuclear pore complexes (NPC). Although exact pathophysiology remains to be elucidated, it is proposed that mutant ALADIN proteins impair the nucleocytoplasmatic shuttling of multi-molecular complexes and make the cells susceptible to oxidative stress, resulting in selective tissue degeneration (6).

Given the rarity of this syndrome, literature related to it is confined to case reports/series, which limits comprehensive understanding of its complete spectrum, especially the genotype–phenotype correlation. Herein, we present our series of eight TAS patients from Western India. Additionally, we did systematic review of the published literature, with the aim of analyzing phenotypic and genotypic spectrum of TAS patients worldwide.

Patients and methods

Cohort 1

A retrospective clinical case records study of TAS patients (cohort 1) managed at a tertiary care center (2004–2016) in Western India was conducted after obtaining approval from ‘Institutional Ethics Committee II, Seth G S Medical College and KEM Hospital, Mumbai’. Waiver of patients’ consent was obtained for this retrospective analysis, though due informed consent had been obtained from patients/parents for the genetic analysis. Clinical diagnosis of TAS was based on the presence of a minimum of two features of the triad. Absence of tears was enquired on history, and wherever possible, diagnosis was confirmed by positive Schirmer’s test, which was defined as <10 mm of moisture on a filter paper, placed under the lower eyelids for 5 minutes. Symptoms suggestive of achalasia were enquired on history, and diagnosis was confirmed by a barium swallow study and/or esophageal manometry.

Biochemical diagnosis of AI was based on 08:00 h serum cortisol (<5 µg/dL) with a simultaneously elevated plasma adrenocorticotropic hormone (ACTH) (>2-fold above the upper limit of the reference interval for the specific assay) (7). Mineralocorticoid (MC) deficiency was defined as elevated (>upper limit of normal for age) plasma renin activity (PRA) level. Serum cortisol was measured by a solid-phase competitive chemiluminescent enzyme immunoassay (Siemens Healthcare) with an analytical sensitivity of 0.2 µg/dL. The intra- and inter-assay coefficients of variability (CVs) of the cortisol assay were 6.9% and 7.3%, respectively. ACTH was measured by a solid-phase, 2-site sequential chemiluminescent enzyme assay (Siemens Healthcare). The intra- and inter-assay CVs were 9.6% and 8.8%, respectively, with an analytical sensitivity of 9 pg/mL. PRA was measured by radio immunoassay (Diasorin, Stillwater, MN, USA). Intra- and inter-assay CV were <0.7% and <10%, respectively, with an analytical sensitivity of 0.018 ng/mL/h.

For genetic testing (AAAS gene), genomic DNA was extracted using a standard protocol. AAAS gene (OMIM#605378, ENST00000209873) was studied by amplification of all 16 exons, including exon–intron boundaries from genomic DNA. After PCR amplification, direct sequencing of the amplicons was carried out using Big Dye Terminator v1.1 Cycle Sequencing kit with an ABI 3100 Genetic Analyzer (Applied Biosystems). The description of sequence variants in DNA and protein sequences were expressed according to the nomenclature of human genome variation society. In silico prediction tools including Mutation Taster, PolyPhen-2 and Sort Intolerant from Tolerant (SIFT) were used to predict the functional significance of variation in sequence.

Cohort 2

Systematic review of published literature (up to February 2016) was done on MEDLINE and Scopus search engines employing following search terms: TAS, Allgrove syndrome, 3A syndrome, 4A syndrome, 5A syndrome, ALADIN protein and AAAS gene. Initial search revealed 277 publications related to TAS of which 209 publications were excluded for various reasons. Two hundred and two publications were excluded due to lack of genotypic details. Two non-English language papers and two papers describing previously reported patients (to avoid duplication) were also excluded. Additionally, three papers describing summary statistics were excluded, as no clear information about phenotypic and genotypic characteristics of individual patients could be discerned. Finally, data of 133 index cases (cohort 2) from 68 publications were analyzed (4, 5, 6, 8, 9, 10, 11, 12, 13,
Phenotype–genotype spectrum

Cohort 1 comprises 8 index TAS patients (3 males, 5 females) managed at our center. The clinical details are summarized in Supplementary Table 1 (see section on supplementary data given at the end of this article). Median age at last follow-up was 17.5 years (range 5.5–28). By then, all patients had manifested three classic components of the triad (alacrima, achalasia and AI), except for one patient (patient 8), who has yet not developed symptoms of achalasia at current age of 5.5 years. Alacrima and AI were present in all (8/8) patients, while achalasia and ND were seen in 7/8 and 4/8 patients, respectively. Median age at presentation was 4.7 years (range: 4–10 years). All patients presented with AI except one patient (patient 6). Patient 6 had presented with ocular discomfort due to alacrima at 5 years of age, though diagnosis of AS was not considered at that time. In all patients, alacrima was the earliest feature noted by parents in early infancy. It was followed by AI with median age at onset of 3.25 years (range: 2.5–10), and achalasia with median age of onset of 14 years (range: 3–20 years). All patients had clinically evident AI with low basal cortisol and elevated ACTH, and none required Synacthen stimulation test for diagnosis. All had normal mineralocorticoid axis as demonstrated by normal PRA levels. Three patients have undergone per oral endoscopic myotomy for severe symptoms of dysphagia and one patient (patient 6) is currently awaiting the procedure. Other patients have mild symptoms of dysphagia and are being managed conservatively. ND was found in 4 patients (50%) after a thorough history and clinical neurological examination. Detailed nerve conduction studies were not done in all patients. The ND in our cohort included generalized tonic–clonic seizure disorder (n=2), moderate mental subnormality (documented by IQ test) (n=1), generalized hyper-reflexia (n=4) and hypernasal speech (n=3). Two patients had palmoplantar hyperkeratosis.

Genotype (cohort 1)

Four patients (4/8) had history of other family members being similarly affected. Two of them had parental consanguinity as well (Fig. 1 and Supplementary Table 1). Genotype analysis of these eight unrelated families revealed five different mutations (novel: 1, reported: 4) in A4AS gene (Fig. 1). Five patients had mutations in homozygous state, two patients in compound heterozygous state while one patient (patient 8) was heterozygous for a novel mutation (Supplementary Table 1). A previously reported frameshift mutation in exon 1 (c.43C>A, p.G14Vfs*45) was the commonest mutation, observed in four families. A deletion in exon 8 (c.762delC; p.S255Vfs*36) was the next common mutation, found in three families. Previously reported mutations in exon 16 (c.1432C>T; p.R478*), exon 9 (c.856C>T; p.R286*) and a novel mutation in exon 9 (c.908T>A, p.L303Q) were found in one patient each.

Phenotype (cohort 2)

The phenotypic details of cohort 2 are described in Table 1. Slight male predominance (57.7%) was observed in overall cohort. Median age at presentation was 5 years (range: 1–42), with majority of patients presenting in first decade of life (80%). AI (36.8%) and achalasia (36.8%) were the common presenting features followed by ND (13.7%) and alacrima (4.2%). In descending order,
the overall prevalence of each feature was: alacrima (99.2%), achalasia (93.2%), AI (90.1%) and ND (79.4%) (Supplementary Table 2).

In the majority of the patients (90.2%), alacrima was noticed by parents since birth/infancy, while in 4 patients, it was noticed later (range: 2–8 years). The singular...
Out of 65 patients with AI, where detailed information was reported, majority (92.3%) had clinical/symptomatic presentation. Only 7.7% (5/65) patients had subclinical AI, in whom diagnosis of AI was established by ACTH stimulation test done as a part of work up, when other components had manifested. Presence or absence of MC deficiency was acknowledged irrespective of description of biochemical parameters was classified as non-definite. Analyses of other features are presented in Table 1. As per Mayo Clinic’s criteria, MC deficiency was classified as definite when detailed description of biochemical evaluation of plasma renin activity and/or plasma aldosterone levels was ascertained. Otherwise, in patients in whom only presence of MC deficiency was acknowledged irrespective of description of biochemical parameters was classified as non-definite.

Patient reported with the absence of alacrima was documented to have normal Schirmer’s test until the age of 18 years (66). AI (median age of onset: 4 years, range: 0–23 years) and achalasia (mean age of onset 8.19 years, s.d. = 7.65 years) manifested earlier than ND (median age of onset: 12 years, range: 1.1–40 years). On sub-analysis of patients in whom age at last follow-up was reported, it was observed that majority of patients who had not manifested achalasia (7/7, 100%) and neurological dysfunction (18/21, 85.71%) at the last follow-up were young (≤18 years).

Table 1 Description of phenotypic details of cohort 2 (n=133 from 68 publications).

| Parameter | Value | Number of patients where relevant information reported |
|-----------|-------|------------------------------------------------------|
| Male:Female | 60/44 | 104 |
| Age at last follow up (years)* | 18.14 (s.d. = 12.9) | 107 |
| Age at presentation (years)** | 5 (range: 1–42) | 90 |
| Percentage of patients presenting at | | |
| ≤10 years | 11 (12.2%) | |
| 11–20 years | 4 (4.5%) | |
| 21–30 years | 2 (2.2%) | |
| 31–40 years | 1 (1.1%) | |
| 41–50 years | | |
| Presenting feature | | 95 |
| AI | 35 (36.8%) | |
| Achalasia | 13 (13.7%) | |
| ND | 4 (4.2%) | |
| Alacrima | 4 (4.2%) | |
| AI and achalasia | 2 (2.1%) | |
| Achalasia and ND | 1 (1.1%) | |
| AI and alacrima | 1 (1.1%) | |
| AI and ND | | |
| Alacrima | 132 (99.2%) | 133 |
| Age at onset** | 0 years (range 0–8) | 41 |
| Age at diagnosis** | 8.6 years (1–60 years) | 61 |
| Prevalence of MC deficiency# | | |
| Non-definite | 3 (12.5%) | 24 (PRA levels available) |
| Definite | 3 (9%) | 33 (PAC levels available) |
| Achalasia | 8.19 years (s.d. = 7.65) | 47 |
| Age at onset* | 10.55 years (s.d. = 8.57) | 68 |
| Al | 12 years (range: 1.1–40) | 2744 |
| Age at onset** | 15.08 years (s.d. = 13.07) | |
| Age at diagnosis* | | |

*Median value (range) is given as data are skewed in distribution; **mean value (s.d.) is given as data is normally distributed; #mineralocorticoid deficiency was classified as definite when detailed description of biochemical evaluation of plasma renin activity and/or plasma aldosterone levels was ascertained. Otherwise, in patients in whom only presence of MC deficiency was acknowledged irrespective of description of biochemical parameters was classified as non-definite.

AI, adrenal insufficiency; MC deficiency, mineralocorticoid deficiency; ND, neurological dysfunction.
elevated PRA levels (3/24, 12.5%) or low PAC levels (3/33, 9%) could be established in few patients only.

Genotype (cohort 2)

34.3% of patients (37 out of 108 patients in whom details of family history were reported) had history of similar affection in one or more family members, while 45.3% of patients (53 out of 117 patients in whom relevant information was mentioned) had history of parental consanguinity (Supplementary Table 2).

Overall, 65 different mutations were reported in 127 patients, 65.4% (n=83) in homozygous state, 33% (n=42) in compound heterozygous state and 1.6% (n=2) in heterozygous state. Mutations were not identified in AAAS gene in 6 patients (4.7%). Common mutations included frameshift (n=19), nonsense (n=19), missense (n=15), and splice-site (n=8) mutations. Additionally, an indel mutation and mutations in the intronic region, regulatory element and 5’ UTR were found in one patient each. Figure 2 collates the various mutations found in AAAS gene (from cohorts 1 and 2). Fourteen mutations were recurrent (defined as occurring in ≥3 unrelated individuals). Some of the recurring mutations exhibit clustering to particular geographical regions (Fig. 3). These include c.1331 + 1G > A (North Africa and USA), c.1423C>T; p.R478* (Europe), c.787T>C; p.S263P (Europe) and c.711delG; p.R258Gfs*33 (China), c.43C>T; p.R14C>A; p.G14Vs*45 (Europe and India, from cohort 1) and c.762delC; p.S255Vs*36 (India, from cohort 1).

Phenotype–genotype correlation analysis

To study phenotype–genotype correlation, patients (from both cohorts 1 and 2) were divided into two groups: Group T-patients with mutations resulting in truncating protein, and group NT-patients with mutations resulting in non-truncating protein. Patients with nonsense mutations, frameshift mutations and deletions were grouped as truncating, while those with missense mutations were grouped as non-truncating ones. Patients having compound heterozygous state with one truncating and other non-truncating mutation were classified in group NT, as it has been observed that patients having at least one missense (non-truncating) mutation have a milder phenotype than those having both truncating ones (21). Three out of 8 splice-site mutations (c.1331 + 1; G>A, c.546-2A>C and c.400-2A>G) were previously reported to result in truncating proteins and hence were classified in group T. Remaining 5 splice-site mutations could not be sub-classified due to the absence of in vitro mRNA studies. These 5 patients with splice-site mutations, three patients who had heterozygous mutations, and six mutation negative patients, were excluded from analysis of genotype–phenotype correlation. The result of genotype–phenotype analysis for remaining 127 patients is shown in Table 2. As compared to NT group, patients in T group had significantly higher prevalence and higher chances of presentation with AI. Moreover, median age of diagnosis of AI in T group was significantly lower than that of NT group. Subclinical AI was found in NT group only. As compared to T group, patients within NT group had significantly higher overall prevalence and higher chances of presentation with ND. However, median age at onset of ND in T group was significantly lower than that of NT group.

Discussion

Triple A syndrome (TAS), though a rare disorder, is an important genetic cause of primary AI in children. Current study includes the first description of Indian series of AS patients (cohort 1). Additionally, it includes systematic
review of phenotype-genotype spectrum of genotyped cases of TAS reported to date (cohort 2).

Although small sample size of our cohort limits statistical comparison with cohort 2, we found that the phenotypic spectrum of our patients was largely similar to that of other ethnicities (cohort 2) except for a lower prevalence of ND in our patients (4/8 patients in cohort 1 vs 80% in cohort 2). Apart from a possible referral bias to an endocrine center, we believe this disparity can be attributed to younger age of our patients. All patients in our cohort without ND are young (5.5–13 years at last follow-up). This conforms with the observation that 87.5% of patients in cohort 2 who have not yet manifested ND were younger than 18 years.

In cohort 2, majority of TAS patients presented in first two decades of life, with either achalasia or AI. Hence TAS, though an uncommon etiology for pediatric achalasia (7–15%) or pediatric AI (1%) per se, should be considered in the etiological workup of these disorders in children (73, 74). Seven patients (8%) in cohort 2 presented in 3rd to 5th decades of life, suggesting that diagnosis of TAS should be considered in adults as well. Interestingly, these seven patients presented either with ND or achalasia, and none of them presented with AI. The reason for this differential mode of disease presentation in adults remains unknown and needs further study.

Analysis of cohort 2 reveals that a patient with TAS can present with any one of the four cardinal features and that the symptoms evolve over a period of time, suggesting TAS to be a progressive disorder. Therefore, it is prudent to exercise high index of suspicion for diagnosis, even in patients presenting with isolated components of TAS. Alacrima, rarely a presenting feature, is the earliest to appear and is present in almost every (99%) patient. Hence, in a patient presenting with AI, achalasia or ND, presence of alacrima can point towards the diagnosis of TAS, while its absence almost rules out this rare condition. Achalasia, present in 93% of patients, was second most prevalent disorder. Its prevalence was higher than what is classically reported in earlier reviews (75%) (1).

AI in TAS is commonly isolated glucocorticoid deficiency. In their original report, Allgrove and coworkers...
Table 2  Comparison of triple A syndrome patients with truncating and non-truncating mutations.

| Parameter                      | Group T Patients with mutations resulting in truncating protein (n=86) | Group NT Patients with mutations resulting in non-truncating protein (n=41) | P value |
|--------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------|---------|
| Mean age at last follow up in years | 16.5 ± 11.8 (69)                                                      | 22.2 ± 13.7 (36)                                                        | 0.068   |
| Percentage of patients with positive family history | 40.8% (29/71)                                                        | 28.1% (9/32)                                                             | 0.27    |
| Percentage of patients having history of consanguinity | 56.7% (42/74)                                                        | 26.3% (10/38)                                                            | 0.003   |
| Percentage of patients presenting with the following feature | | | | <0.001 |
| Adrenal insufficiency | 55% (33/60)                                                          | 12.5% (4/32)                                                             | 0.118   |
| Achalasia                  | 30% (18/60)                                                          | 46.8% (15/32)                                                            | 0.02    |
| Alacrimia                  | 5% (3/60)                                                            | 21.8% (7/32)                                                             | 0.12    |
| Neurological dysfunction   | 5% (2/60)                                                            | 15.6% (5/32)                                                             |         |
| Mixed presentation         | 40.8% (29/71)                                                        | 28.1% (9/32)                                                             |         |
| Median age at presentation in years | 5 years (62)                                                       | 5 years (28)                                                             | 0.159   |
| Prevalence of following features | 98.8% (85/86)                                                      | 75.6% (31/41)                                                            | <0.001  |
| Adrenal insufficiency      | 93% (80/86)                                                          | 95.12% (39/41)                                                           | 1       |
| Achalasia                  | 100% (86/86)                                                         | 97.5% (40/41)                                                            | 0.32    |
| Alacrimia                  | 73.4% (58/79)                                                        | 95.12% (39/41)                                                           | 0.003   |
| Neurological dysfunction   | 19% (8/42)                                                           | 21.7% (5/23)                                                             | 0.75    |
| Mineralocorticoid deficiency| 17.4% (15/86)                                                       | 24.3% (10/41)                                                            | 0.35    |
| Skin manifestations         | 8 ± 7.3 years (34)                                                   | 8.9 ± 7.6 years (14)                                                     | 0.685   |
| Mean age at onset (years)   | 10.3 ± 7.9 years (42)                                                | 10.7 ± 8.7 years (24)                                                   | 0.844   |
| Mean age at diagnosis (years) | 13 (23)                                                            | 13 (23)                                                                  | 0.02    |
| Alacrimia                  | 0 (30)                                                               | 0 (11)                                                                   | 0.387   |
| Median age at onset (years) | 8.25 (39)                                                            | 8.25 (39)                                                                |         |
| Median age at diagnosis (years) | 13 (23)                                                            | 13 (23)                                                                  |         |
| Adrenal insufficiency       | 3.5 years (36)                                                       | 5.75 years (8)                                                           | 0.27    |
| Median age at onset (years) | 5.15 years (48)                                                      | 9.3 years (18)                                                           | 0.02    |
| Median age at diagnosis (years) | 17.2 ± 16 years (22)                                                | 17.2 ± 16 years (22)                                                    | 0.31    |
| Neurological dysfunction    | 6.5 (12)                                                             | 12 years (15)                                                            | 0.04    |
| Mean age at onset (years)   | 13.4 ± 8.1 years (24)                                                | 17.2 ± 16 years (22)                                                    |         |
| Prevalence of subclinical AI | 0% (0/48)                                                            | 22.2% (4/18)                                                             | 0.008   |

Figures in parenthesis indicate the number of patients in whom information about respective parameter was available.
described it as a variant of familial glucocorticoid deficiency with histopathological evidence of a preserved zona glomerulosa (3). Later, MC deficiency was also reported in TAS (51, 71, 72). Grant and coworkers reported 3 patients to be MC deficient (all 3 with typical electrolyte abnormalities and two with additional elevated PRA) in a cohort of 20 TAS patients, suggesting 15% prevalence of MC deficiency in TAS (75). In close analysis of cohort 2, we found that definite MC deficiency was uncommon (12.5% (3/24) in those with PRA levels reported; 9% (3/33) in those with PAC levels reported). Similarly, none of the patients in cohort 1 had MC deficiency as documented with normal PRA levels. These findings emphasize the need of establishing definite diagnosis of MC deficiency with study of PAC and PRA levels, before starting fludrocortisone replacement. The pathophysiology of MC axis involvement remains unknown and may be proposed to be due to progressive degeneration of zona glomerulosa and/or autonomic dysfunction.

Half of patients in cohort 1 and one-third (34.3%) of patients in cohort 2 were familial cases. Additionally, there was higher prevalence of parental consanguinity (45%) in patients of cohort 2, which emphasizes autosomal recessive mode of inheritance for TAS. The current study revealed 67 different mutations in AAAS gene, including a novel mutation from cohort 1. The majority (7/8) patients in cohort 1 and 94% in cohort 2) had mutations in homozygous or compound heterozygous state consistent with AR inheritance. Two patients in cohort 2 were heterozygous for mutations (58, 72) (c.856C>T (p.R286*) and c.1331+1; G>A (IVS14+1 G>A)), which have been previously reported in homozygous as well as compound heterozygous states (4, 38, 44, 72). Interestingly, in these previous reports, familial segregation analysis documented no clinical phenotype of disease in healthy parents or unaffected siblings, who were heterozygous (carriers) for these mutations. The plausible explanation for this phenomenon could be the presence of another mutation in noncoding sequences of second allele of AAAS gene, which remained unidentified with current detection methods or another unknown gene mutation, which affects the expression and/or function of AAAS gene.

Six patients from cohort 2 tested negative for mutations in AAAS gene (47, 49, 58, 68). This can be postulated to be due to unidentified large deletions (missed on Sanger sequencing) or mutations in uncharted intronic or regulatory regions. In few mutation-negative TAS families, even linkage to markers of the AAAS gene region on 12q13 was found to be negative (76). Hence, the possibility of mutations in genes other than AAAS gene with phenotype similar to TAS cannot be ruled out, further signifying the genetic heterogeneity of TAS.

Mutations were found throughout the AAAS gene, suggesting no hotspots. However, based on the observation of geographic clustering of apparently unrelated patients with same mutations, several authors have suggested regional founder effects for certain recurring mutations, which were substantiated by haplotype analysis (4, 5, 33, 41, 44). Based on haplotype analysis, Genin and coworkers predicted that c.1331 + 1G>A mutation originated in North African population 1000–1175 years ago (77). In our analysis, we identified 15 recurrent mutations, with few exhibiting regional clustering. These represent higher background (region specific) carrier rate, suggesting a common ancestral origin. Thus, ethnic origin of a patient may help in targeted molecular diagnosis of TAS. Facilitation of genetic diagnosis by this approach has been attempted by Kallabi and coworkers who performed targeted sequencing precisely for the region of AAAS gene (172-bp fragment that covers the junction between exon 14 and intron 14) corresponding to commonly described North African ancestral mutation (c.1331 + 1G>A) in two Libyan AS families and confirmed the presence of same mutation (13). Kallabi and coworkers further proposed that doing restricted enzymatic digestion by Mva I of the targeted PCR product can facilitate family screening of affected individuals (13).

Even before genetic etiology of TAS could be elucidated, intra-familial variability in clinical phenotype was well recognized (1, 78). Thereafter, study of genotype–phenotype correlation in TAS patients was based on observing variability in clinical manifestations in patients having same individual mutation (20, 41, 54). This approach revealed the absence of a consistent genotype–phenotype correlation, which was proposed to be due to effect of other modifying genes or environmental factors on the phenotype of TAS.

Few authors have observed that the patients with missense mutations had different phenotypes than those with truncating mutations (21). We used similar approach to study the genotype–phenotype correlation in our study and observed significant clinical differences between the two groups. Patients in T group were more likely to present with symptomatic AI, diagnosed to have AI at younger age and have overall higher prevalence of AI as compared to NT group. Prevalence/presentation of alacrima and achalasia did not differ among these groups. Patients in NT group were more likely to present with ND, with onset of ND at later age and have higher prevalence...
of ND as compared to T group. With the underlying causative mechanisms unknown, our observation of differing clinical profiles of the two groups calls for future research. In vitro studies have shown that mutations truncating N or C terminals, and most non-truncating mutations, especially those in WD repeat region result in mis-localisation of ALADIN protein, potentially causing functional disruption of interaction of mutant ALADIN with other associated proteins (79). A possible interaction of ALADIN with PGRMC2, a regulator of the cell cycle, and participation of ALADIN in cell division by spatial regulation of Aurora A was described recently (80, 81). It can be speculated that during process of cell division, missense mutations (non-truncating) with the presence of a functionally impaired protein may have different consequences compared to that of a truncated protein, which in most cases, undergoes degradation by the ubiquitin–proteasome pathway, accounting for phenotypic differences in clinical features.

Most previous reports on TAS have limitation of small sample size. Besides being the first description of largest Indian series of genetically proven TAS patients, the strength of our study includes collation of individual data of genotyped TAS patients worldwide. We believe that our study adds to the comprehensive understanding of phenotypic and genotypic spectrum of this rare disorder. However, the study has important limitation of non-uniformity of data, as complete phenotypic information was not available for each reported patient. Also, phenotypic information of pre-2000 era (before AAAS gene was described) is not included in the current study, which may make the phenotypic prevalence data of cohort 2 not completely representative. Progressive nature of the syndrome forms an additional limitation for genotype-phenotype correlation (62).

**Conclusion**

Clinical profile of Indian TAS patients is largely similar to that of patients of other ethnicities. Although TAS is predominantly a disorder of children and adolescents, it can manifest in adulthood up to 5th decade of life. Alacrima is the earliest and most consistent finding of it can manifest in adulthood up to 5th decade of life. predominately a disorder of children and adolescents, to that of patients of other ethnicities. Although TAS is a rare clinicopathological entity, this study adds to the comprehensive understanding of phenotypic and genotypic spectrum of this rare disorder. However, the study has important limitation of non-uniformity of data, as complete phenotypic information was not available for each reported patient. Also, phenotypic information of pre-2000 era (before AAAS gene was described) is not included in the current study, which may make the phenotypic prevalence data of cohort 2 not completely representative. Progressive nature of the syndrome forms an additional limitation for genotype-phenotype correlation (62).

Phenotypic profile of patients with truncating mutations differs systematically from that of patients with non-truncating mutations. Future research is warranted to put this observation in perspective.

**Supplementary data**

This is linked to the online version of the paper at [http://dx.doi.org/10.1530/EC-17-0255](http://dx.doi.org/10.1530/EC-17-0255).

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was supported by a DFG grant HU 895/5-1 and HU 895/5-2 (Clinical Research Unit 252) to A.H.

**References**

1. Clark AJ & Weber A. Adrenocorticotropic hormone insensitivity syndromes. *Endocrine Reviews* 1998 19 828–843. (doi:10.1210/edrv.19.6.0351)
2. Sarathi V & Shah NS. Triple A syndrome. *Advances in Experimental Medicine and Biology* 2010 685 1–8. (doi:10.1007/978-1-4419-6448-9_1)
3. Allgrove J, Clayden GS, Grant DB & Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. *Lancet* 1978 1 1284–1286. (doi:10.1016/S0140-6736(78)91268-0)
4. Handschug K, Sperling S, Yoon S-JK, Hennig S, Clark AJ & Huebner A. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. *Human Molecular Genetics* 2001 10 283–290. (doi:10.1093/hmg/10.3.283)
5. Tullio-Pelet A, Salomon R, Hadi-Rabia S, Mugnier C, de Laet MH, Chauuchi B, Bakiri F, Brottier P, Cattolico L, Penet C, et al. Mutant WD-repeat protein in triple-A syndrome. *Nature Genetics* 2000 26 332–335. (doi:10.1038/318642)
6. Hirano M, Furiya Y, Asai H, Yasui A & Ueno S. ALADIN482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome. *PNAS* 2006 103 2298–2303. (doi:10.1073/pnas.0505991103)
7. Bornstein SR, Allolio B, Aih W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism* 2016 101 364–389. (doi:10.1210/jc.2015-1710)
8. Bustanji H, Sahar B, Huebner A, Ajlouni K, Landgraf D, Hamamy H & Koehler K. Triple A syndrome with a novel indel mutation in the AAAS gene and delayed puberty. *Journal of Pediatric Endocrinology and Metabolism* 2015 28 933–936. (doi:10.1515/jpem-2014-0401)
9. Hansen ML, Frederiksen AL & Juhl CB. Novel mutation in the AAAS gene in a severely affected triple-A syndrome patient. *Endocrinology and Metabolic Syndrome* 2015 4 3. (doi:10.4172/2161-1017.1000186)
10. Sanghvi J, Asati AA, Kumar R & Huebner A. Novel mutations in a patient with triple A syndrome. *Indian Pediatrics* 2015 52 805–806. (doi:10.1007/s13312-015-0722-y)
11. Li W, Gong C, Qi Z, Wu D & Cao B. Identification of AAAS gene mutation in triple A syndrome: a report of three cases. *Experimental and Therapeutic Medicine* 2015 10 1277–1282. (doi:10.3892/etm.2015.2677)
Phenotype–genotype spectrum

Endocrine Connections

26 Wallace I R & Hunter S J. AAA syndrome—adrenal insufficiency,

21 Ikeda M, Hirano M, Shinoda K, Katsumata N, Furutama D,

20 Dumic M, Barišić N, Kusek V, Stingl K, Skegro M, Stanimirovic A,

17 Yang H, Zhang H, Lu L, Wang O, Xing X, Zhang M & Lu Z. Clinical

16 Bizzarri C, Benevento D, Terzi C, Huebner A & Cappa M. Triple A

15 Cherif Ben Abdallah L, Lakhoua Y, Nagara M, Khiari K, Elouej S,

14 Aragona P, Rania L, Roszkowska AM, Puzzolo D, Micali A, Pisani A,

12 Zimmer V, Vanderwinden J M, Zimmer A, Ostertag D,

24 Yassaee VR, Soltani Z & Ardakani BM. Mutation spectra of the AAAS

11–13. mutation of the AAAS gene.

39–39) genetical findings in eight patients with triple A syndrome.

39-39) Genetic findings in eight patients with triple A syndrome.

Koehler K & Huebner A. Two siblings with triple A syndrome and novel

of triple A (Allgrove) syndrome in a Greek family.

77 effects of two genetic disorders.

in a patient with genetic growth hormone insensitivity: phenotypic

effects of two genetic disorders.

Experimental and Clinical Endocrinology and Diabetes 2012 118 530–536.

Journal of Neurological Sciences 2010 299–301. (doi:10.1515/jnem-2011-01348.x)

Luigetti M, Pizzuti A, Bartoletti S, Houlden RG, Ibáñez L, Bottino I,

Madia F, Conte A, Tonali PA & Sabatelli M. Triple A syndrome: a novel

compound heterozygous mutation in the AAAS gene in an Italian

patient without adrenal insufficiency. Journal of Neurological Sciences 2010 299 150–152.

Villanueva-Mendoza C, artínez-Guzmán O, Rivera-Farra D & Zenteno JC. Triple A or Allgrove syndrome. A case report with ophthalmic abnormalities and a novel mutation in the AAAS gene. Ophthalmic Genetics 2009 30 45–49.

Huyhn T, McGown I, Nyuny O, Cowley D, Harris M, Cotterill AM & Leong GM. A novel V185DfsX4 mutation of the AAAS gene in a 2-year-old boy with triple A syndrome. Clinical Pediatric Endocrinology 2009 18 73–75. (doi:10.1297/cpe.18.73)

Messina ME, Autunno M, Koehler K, Russo M, Aringo T, Crisafulli G,

Huebner A & De Luca F. Upper and lower motor neuron involvement as presenting manifestation of triple A syndrome. Journal of Endocrinological Investigations 2009 32 482–483. (doi:10.1007/s00398-013-0047-2)

Thümmler S, Huebner A & Bacchler-Sadoul E. Triple A syndrome: two novel mutations in the AAAS gene. BM Case Reports 2009 09:913 –913. (doi:10.1007/bcr09.2008.0984)

Toromanovic A, Tahirjov H, Milenkovic T, Koehler K, Kind B,

Zdravkovic D, Hasanholdzic M & Huebner A. Clinical and molecular

genetic findings in a 6-year-old Bosnian boy with triple A syndrome. European Journal of Pediatrics 2009 168 317–320. (doi:10.1007/s00431-008-0758-2)

Milenkovic T, Koehler K, Krumholz M, Zivanovic S, Zdravkovic D & Huebner A. Three siblings with triple A syndrome with a novel frameshift mutation in the AAAS gene and a review of 17 independent patients with the frequent p. Ser263Pro mutation. European Journal of Pediatrics 2008 167 1049–1055. (doi:10.1007/s00431-007-0640-7)

Koehler K, Brockmann K, Krumholz M, Kind B, Bönneemann C,

Gärtner J & Huebner A. Axonal neuropathy with unusual pattern of amyotrophy and alacrima associated with a novel AAAS mutation
Phenotype–genotype spectrum of triple A syndrome

1. Introduction

Triple A syndrome (Allgrove syndrome) is a rare autosomal recessive disorder characterized by achalasia, adrenal insufficiency, and intractable constipation. The diagnosis is usually made in childhood or adolescence, and the disease can be progressive.

2. Pathogenesis

The disease is caused by mutations in the AAAS gene, which encodes the aldehyde dehydrogenase 1D1 enzyme. Mutations lead to enzyme deficiency, resulting in the accumulation of propionylcarnitine and acylcarnitine in plasma, a hallmark of the disease.

3. Clinical Manifestations

- Achalasia: The most common manifestation, characterized by difficulty swallowing and vomiting.
- Adrenal insufficiency: Often diagnosed late in the disease, with symptoms of fatigue, weight loss, and hypotension.
- Intractable constipation: A hallmark of the disease, often leading to surgical interventions.

4. Diagnosis

- Clinical: Characteristic triad of achalasia, adrenal insufficiency, and constipation.
- Genetic: AAAS gene sequencing is definitive, with mutations identified in most cases.

5. Management

- Medical: Symptomatic treatment for achalasia and adrenal insufficiency.
- Surgical: Esophageal dilatation and in situ esophagoplasty for achalasia.
- Palliative: Management of complicated constipation.

6. Conclusion

Triple A syndrome is a challenging disorder with significant impact on quality of life. Early diagnosis and multidisciplinary approach are crucial for optimal management.

References

[1] Dusek T, Korsic M, Koehler K, Huenber A, Ziegler S & Deschauer M. Triple A syndrome mimicking ALS. Amyotrophic Lateral Sclerosis 2008; 9: 315–317.
[2] Chang AJ, Kline MM, Currie Y, Perez MO, Hartiala J, Wijesuriya H, et al. Successful treatment of achalasia in children with Gastrointestinal Endoscopy 2003; 42: 331–335.
[3] Arruda CA, Fraga JC, Goldani HA. Diagnosis, misdiagnosis, and management of adrenal insufficiency in children: twenty years experience at the Pediatric Division of Clinics of São Paulo. Hormone Research in Pediatrics 2003; 59: 28–33.
[4] Brooks BP, Kraja T, Caruso RC, Stuart C, Ludlow J & Stratakis CA. Triple-A syndrome: a rare etiology of adult achalasia. Digestive Diseases and Sciences 2005; 50: 440–442.
[5] Roubougera A, Aparisi E, Vidalilhet M, Mignot C, Tuilipo-A, Lyonnnet S & de Villemeur TB. Myoclonus and generalized digestive dystomyt in triple A syndrome with AAAS gene mutation. Movement Disorders 2004; 19: 344–346.
[6] Barat P, Goisicet C, Tullio-Pelet A, Puel O, Lobbies C & Barthelemy A. Phenotypic heterogeneity of an AAAS gene mutation. Acta Paediatrica 2004; 93: 1257–1259.
[7] Reshmi-Skajara S, Huenber A, Handschug K, Finegold DN, Clark AJ & Gollin SM. Chromosomal fragility in patients with triple A syndrome. American Journal of Medical Genetics 2003; 117A: 30–36.
[8] Pipic I, Huenber A, Persic M, Handschug K & Pavletic M. Triple A syndrome: genotype–phenotype assessment. Clinical Genetics 2003; 63: 415–417.
[9] Kimber J, McLean BN, Prevett M & Hammar SR. Allgrove or 'A' syndrome: an autosomal recessive syndrome causing multisystem neurological disease. Journal of Neurology, Neurosurgery and Psychiatry 2003; 74: 654–657.
[10] Houlden H, Smith S, de Carvalho M, Blake J, Mathias C, Wood NW & Reilly MM. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain 2002; 125: 2681–2690.
[11] Goizet C, Catargi T, Tison F, Tullio-Pelet A, Hlad-Rabiia S, Pujol F, Lagueny A, Lyonnnet S & Lacoppe D. Progressive bulbo-sphincter amyotrophy in triple A syndrome associated with AAAS gene mutation. Neurology 2002; 59: 962–965.
[12] Katsurama N, Hirose H, Kashiwazaki K. Analysis of the AAAS gene in a Japanese patient with triple A syndrome. Endocrine Journal 2002; 49: 49–53.
[13] Schmittmann-Ohters K, Huenber A, Richter-Unruh A & Hauffa BP. Clinical and molecular findings in a 6-year old Turkish boy with triple A syndrome. Hormone Research in Pediatrics 2002; 58: 96–100.
[14] Sandrini F, Farmakidis C, Kirschner LS, Wu SM, Tullio-Pelet A, Lyonnnet S, Metzger DL, Bourdon CJ, Tison F, et al. Spectrum of mutations of the AAAS gene in Allgrove syndrome: lack of mutations in six kindreds with isolated resistance to corticotropin. Journal of Clinical Endocrinology and Metabolism 2001; 86: 5433–5437.
[15] Hallal C, Kieling CO, Nunes DL, Ferreira CT, Peterson G, Barros SG, Ardura CA, Fraga JC, & Goldani HA. Diagnosis, misdiagnosis, and associated diseases of achalasia in children and adolescents: a twelve-year single center experience. Pediatric Surgery International 2012; 28: 1211–1217.
[16] Perry R, Kech O, Paquette J, Huet C, Van Vliet G & Dea C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. Journal of Clinical Endocrinology and Metabolism 2005; 90: 3243–3250.
75 Grant DB, Barnes ND, Dumic M, Ginalska-Malinowska M, Milla PJ, von Petrykowski W, Rowland BJ, Steendijk R, Wales JH & Werder E. Neurological and adrenal dysfunction in the adrenal insufficiency/alacrima/achalasia (3A) syndrome. Archives of Disease in Child 1993 68 779–782. (doi:10.1136/adc.68.6.779)
76 Huebner A, Kaindl AM, Knobeloch KP, Petzold H, Mann P & Koehler K. The triple A syndrome is due to mutations in Aladin, a novel member of the nuclear pore complex. Endocrine Research 2004 30 891–899. (doi:10.1081/ERC-200044138)
77 Genin E, Tulip-Pelet A, Bégot I, Lyonnet F & Abel L. Estimating the age of rare disease mutations: the example of triple-A syndrome. Journal of Medical Genetics 2004 41 445–449. (doi:10.1136/jmg.2003.017962)
78 Heinrichs C, Tsigos C, Deschepper J, Drews R, Collu R, Dugardeyn C, Goyens P, Ghanem GE, Bosson D, Chrousos GP, et al. Familial adrenocorticotropic unresponsiveness associated with alacrima and achalasia: biochemical and molecular studies in two siblings with clinical heterogeneity. European Journal of Pediatrics 1995 154 191–196. (doi:10.1007/BF01954269)
79 Cronshaw JM & Matunis MJ. The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. PNAS 2003 100 5823–5827. (doi:10.1073/pnas.1031047100)
80 Jühlen R, Landgraf D, Huebner A & Koehler K. Identification of a novel putative interaction partner of the nucleoporin ALADIN. Biology Open 2016 5 1697–1705. (doi:10.1242/bio.021162)
81 Carvalhal S, Ribeiro SA, Arocena M, Kasciukovic T, Temme A, Koehler K, Huebner A & Griffis ER. The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation. Molecular Biology of the Cell 2015 26 3424–3438. (doi:10.1091/mbc.E15-02-0113)

Received in final form 17 October 2017
Accepted 25 October 2017